IBRX Earnings & Financial Statements
ImmunityBio, Inc.
$10.04
+$0.13(+1.26%)
55
Overall
40
Value
75
Tech
50
Quality
Market Cap
$10.50B
Volume
13.37M
52W Range
$1.95 - $12.43
Target Price
$12.60
IBRX earnings and financial statements: ImmunityBio, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
IBRX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $113.29M | $14.74M | $622.0K | $240.0K | $934.0K |
| Cost of revenue | $753.0K | - | - | - | - |
| Operating income | -$256.03M | -$344.18M | -$362.25M | -$351.30M | -$330.28M |
| EBITDA | -$284.54M | -$333.85M | -$516.79M | -$313.30M | -$320.75M |
| Net income | -$351.40M | -$413.56M | -$583.20M | -$416.57M | -$346.79M |
| EPS (diluted) | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $501.90M | $382.93M | $504.45M | $362.36M | $468.91M |
| Total liabilities | $1.00B | $871.06M | $1.09B | $812.18M | $712.82M |
| Shareholders’ equity | -$500.47M | -$489.10M | -$586.99M | -$447.33M | -$242.17M |
| Cash and equivalents | $88.33M | $143.43M | $265.45M | $104.64M | $181.10M |
| Long-term debt | $358.06M | $319.23M | $876.89M | $289.22M | $37.07M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$304.94M | -$391.24M | -$366.76M | -$337.51M | -$274.42M |
| Capital expenditure | -$4.25M | -$6.89M | -$30.58M | -$99.39M | -$33.56M |
| Free cash flow | -$309.19M | -$398.12M | -$397.34M | -$436.90M | -$307.98M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IBRX | $10.04 | +1.3% | 13.37M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |